SwitzerlandSwitzerland

Biomass conversion could open 295bn US-$ market by 2030

30.06.2010

Geneva – Conversion of biomass to biofuels, chemicals, energy and heat has the potential to create a US$295 bn market by the year 2030 and create 800,000 new jobs, according to a report published by the World Economic Forum (WEF). The report, published in co-operation with the industrial biotechnology companies Royal DSM, Novozymes, the chemical corporation DuPont and the plastics manufacturer Braskem, sees huge potential particularly in building biorefineries that convert renewable resources carbon dioxide neutrally into energy, biofuels, chemicals and bioplastics. The report „The Future of Industrial Biorefinieries“ estimates that creation of a biomass value chain can generate revenues of US$15m for agricultural inputs, US$89bn for biomass production, US-$30 for biomass trading, US-$ 10bn for berefining inputs, US-$ 80 bn for fermentation of biofuels, US$6bn for bioplastic production, and US$65bn for biomass-based power and heat. However, the report also says that high investment and infrastructure costs as well as restricted availability of biomass could hamper biomass conversion to become a commercial success at the industry scale. On the other side, biorefineries have the potential to reshape today’s industrial landscape.“ We are at the doorstep of a transition to a greener, more sustainable future, with the bio-based economy as the key enabler“ commented Feike Sijbesma, CEO of DSM, the world leader in fermentative biomass conversion. The report confirms he need for biomass replacement that comes at oil’s low prices but without the high cost.“ Said Stehen Rijsgaard, CEO of Novozymes, the world champion in enzyme technology. Braskem is planning a production site in Brazil to produce biobased polyethylene at 200.000 metric tons per year. DuPont has produced the platform chemical 1,3 propane diol (PDO) on an industrial scale since 2006, while Novozymes has developed an enzyme cocktail for biofuel production from wood waste and grass.

SwitzerlandSwitzerland

30.03.2012

Basel/Hinxton (UK) – Two European teams have created huge repositories of cancer genomics data that help predict drug response. Swiss Novartis and the Boston-based Broad Institute have combined data obtained from large-scale...

SwitzerlandSwitzerland

27.03.2012

London/Lausanne – The global private equity firm Celtic Therapeutic L.L.L.P. believes in the power of antibody-drug conjugates (ADCs). It is investing $50m in a new Switzerland-based company called ADC Therapeutics Sarl which...

SwitzerlandSwitzerland

26.03.2012

Basel/Vienna - Following promising results from a Phase III study, Roche has submitted a regulatory application to EMA for subcutaneous Herceptin (trastuzumab) to treat HER2-positive breast cancer. Roche said subcutaneous...

SwitzerlandSwitzerland

09.03.2012

After the US Food & Drug Administration forced Swiss generics giant Sandoz AG to update its production facilities in Quebec, there are now fears that supplies of some medicines could grow tight in Canada. The regulatory authority...

SwitzerlandSwitzerland

08.03.2012

The hepatitis C space has seen a string of large deals in the last weeks that include a US$11bn buyout of Pharmasset by Gilead. Now Novartis is also trying to get in the game with the purchase of a global exclusive licence from...

SwitzerlandSwitzerland

06.03.2012

Allschwil – Swiss Actelion Ltd. has strengthened its commercial offerings by securing rights in certain countries to Auxilium’s biotech drug Xiaflex for treating tissue buildup under the skin. The US pharma is to receive US$10m...

SwitzerlandSwitzerland

06.03.2012

Zug – Life Sciences specialist HBM partners has raised €90m in the first close of its HBM BioCapital II fund, which will invest in revenue-generating companies in the pharmaceuticals, medical device and diagnostics sectors....

SwitzerlandSwitzerland

05.03.2012

Stans – Mondobiotech, a drug discovery company in troubled waters, could soon be under Italian ownership: The Swiss biotech announced it has entered into exclusive negotiations with Milan-based provider of pharmaceutical and...

Displaying results 1 to 10 out of 276

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-switzerland/article/biomass-conversion-could-open-295bn-us-market-by-2030.html

Stock list

All quotes

TOP

  • SERODUS (N)3.05 NOK7.02%
  • SUMMIT (UK)4.03 GBP3.87%
  • DEINOVE (F)13.32 EUR2.46%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • ALMIRALL (E)11.07 EUR-7.13%

TOP

  • SANTHERA (CH)70.65 CHF114.1%
  • CELLECTIS (F)13.54 EUR112.6%
  • ADDEX (CH)4.54 CHF108.3%

FLOP

  • THROMBOGENICS (B)8.51 EUR-51.5%
  • MERCK KGAA (D)63.67 EUR-50.6%
  • VERONA PHARMA (UK)1.20 GBP-42.9%

TOP

  • SANTHERA (CH)70.65 CHF3111.4%
  • GW PHARMACEUTICALS (UK)443.50 GBP843.6%
  • PAION (D)2.71 EUR310.6%

FLOP

  • CYTOS (CH)0.24 CHF-93.1%
  • EVOCUTIS (UK)0.21 GBP-92.6%
  • THROMBOGENICS (B)8.51 EUR-73.6%

No liability assumed, Date: 12.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events